Literature DB >> 1674549

Blocking of human immunodeficiency virus infection depends on cell density and viral stock age.

S P Layne1, M J Merges, J L Spouge, M Dembo, P L Nara.   

Abstract

Quantitative infectivity assays were used to study how the blocking activity of soluble CD4 (sCD4) is affected by sCD4 concentration, target cell density, and viral stock age. During incubation with 20 nM sCD4, human immunodeficiency virus type 1 (HIV-1) stocks underwent irreversible inactivation. In contrast, inactivation with 2 nM sCD4 was almost entirely reversible. At lower sCD4 concentrations (less than or equal to 2 nM) and target cell densities of 6.25 x 10(4) ml-1, sCD4 blocking activity for HIV-1 gave a gp120-sCD4 association constant (Kassoc) of 1.7 x 10(9) M-1, which agrees with chemical measurements. At the higher density of 1.6 x 10(7) cells ml-1, however, the blocking activity was 20-fold less. During incubation of HIV-1 stock optimized for infectivity by rapid harvest, sCD4 blocking activity increased 20-fold during a 3-h window. These results show that competitive blocking activity depends strongly on target cell density and virion age. Thus, unappreciated variations in HIV stocks and assay conditions may hinder comparisons of blockers from laboratory to laboratory, and the age of HIV challenge stocks may influence studies of drug and vaccine efficacy. The results also suggest that blocking of viral particles in lymphoid compartments will require very high competitive blocker concentrations, which may explain the refractory outcomes from sCD4-based drug trials in humans.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1674549      PMCID: PMC240987     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  59 in total

1.  Morphometric analysis of recombinant soluble CD4-mediated release of the envelope glycoprotein gp120 from HIV-1.

Authors:  R Kirsh; T K Hart; H Ellens; J Miller; S A Petteway; D M Lambert; J Leary; P J Bugelski
Journal:  AIDS Res Hum Retroviruses       Date:  1990-10       Impact factor: 2.205

2.  Soluble CD4 molecules neutralize human immunodeficiency virus type 1.

Authors:  A Traunecker; W Lüke; K Karjalainen
Journal:  Nature       Date:  1988-01-07       Impact factor: 49.962

3.  A soluble CD4 protein selectively inhibits HIV replication and syncytium formation.

Authors:  R E Hussey; N E Richardson; M Kowalski; N R Brown; H C Chang; R F Siliciano; T Dorfman; B Walker; J Sodroski; E L Reinherz
Journal:  Nature       Date:  1988-01-07       Impact factor: 49.962

4.  Atomic structure of a fragment of human CD4 containing two immunoglobulin-like domains.

Authors:  J H Wang; Y W Yan; T P Garrett; J H Liu; D W Rodgers; R L Garlick; G E Tarr; Y Husain; E L Reinherz; S C Harrison
Journal:  Nature       Date:  1990-11-29       Impact factor: 49.962

5.  The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain.

Authors:  P J Maddon; A G Dalgleish; J S McDougal; P R Clapham; R A Weiss; R Axel
Journal:  Cell       Date:  1986-11-07       Impact factor: 41.582

6.  Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization.

Authors:  J A McKeating; A McKnight; J P Moore
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

7.  Loss of envelope antigens of HTLV-III/LAV, a factor in AIDS pathogenesis?

Authors:  H R Gelderblom; H Reupke; G Pauli
Journal:  Lancet       Date:  1985-11-02       Impact factor: 79.321

8.  Dissociation of gp120 from HIV-1 virions induced by soluble CD4.

Authors:  J P Moore; J A McKeating; R A Weiss; Q J Sattentau
Journal:  Science       Date:  1990-11-23       Impact factor: 47.728

9.  Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1.

Authors:  K Javaherian; A J Langlois; G J LaRosa; A T Profy; D P Bolognesi; W C Herlihy; S D Putney; T J Matthews
Journal:  Science       Date:  1990-12-14       Impact factor: 47.728

10.  Direct measurement of soluble CD4 binding to human immunodeficiency virus type 1 virions: gp120 dissociation and its implications for virus-cell binding and fusion reactions and their neutralization by soluble CD4.

Authors:  J P Moore; J A McKeating; W A Norton; Q J Sattentau
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

View more
  23 in total

1.  Statistical analysis of sparse infection data and its implications for retroviral treatment trials in primates.

Authors:  J L Spouge
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

2.  Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates.

Authors:  J P Moore; J A McKeating; Y X Huang; A Ashkenazi; D D Ho
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

3.  Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development.

Authors:  M R Boyd; K R Gustafson; J B McMahon; R H Shoemaker; B R O'Keefe; T Mori; R J Gulakowski; L Wu; M I Rivera; C M Laurencot; M J Currens; J H Cardellina; R W Buckheit; P L Nara; L K Pannell; R C Sowder; L E Henderson
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

Review 4.  Antiviral therapy in human immunodeficiency virus infections. Current status (Part II).

Authors:  E Sandström; B Oberg
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

5.  Quantitative model of antibody- and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type 1.

Authors:  P J Klasse; J P Moore
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

6.  Modeling how many envelope glycoprotein trimers per virion participate in human immunodeficiency virus infectivity and its neutralization by antibody.

Authors:  Per Johan Klasse
Journal:  Virology       Date:  2007-09-07       Impact factor: 3.616

7.  Viral multiplicity of attachment and its implications for human immunodeficiency virus therapies.

Authors:  J L Spouge
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

Review 8.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

9.  Neutralization of Virus Infectivity by Antibodies: Old Problems in New Perspectives.

Authors:  P J Klasse
Journal:  Adv Biol       Date:  2014-09-09

10.  Two mechanisms of soluble CD4 (sCD4)-mediated inhibition of human immunodeficiency virus type 1 (HIV-1) infectivity and their relation to primary HIV-1 isolates with reduced sensitivity to sCD4.

Authors:  S L Orloff; M S Kennedy; A A Belperron; P J Maddon; J S McDougal
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.